The aim of this study was to evaluate the efficacy of two classes of glucose-lowering medications, namely SGLT-2i and GLP-1 RAs, for the treatment of T2DM when used in a real-life clinical practice with other glucose, blood pressure (BP), and lipid-lowering medication. Here, GCG is linked to type 2 diabetes mellitus.